Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History.
clonal evolution
glioblastoma
multiregional sequencing
spatial heterogeneity
temporal heterogeneity
tumor phylogeny
tumor progression
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
17
03
2021
revised:
07
04
2021
accepted:
20
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Glioblastoma is one of the most common and lethal primary neoplasms of the brain. Patient survival has not improved significantly over the past three decades and the patient median survival is just over one year. Tumor heterogeneity is thought to be a major determinant of therapeutic failure and a major reason for poor overall survival. This work aims to comprehensively define intra- and inter-tumor heterogeneity by mapping the genomic and mutational landscape of multiple areas of three primary IDH wild-type (IDH-WT) glioblastomas. Using whole exome sequencing, we explored how copy number variation, chromosomal and single loci amplifications/deletions, and mutational burden are spatially distributed across nine different tumor regions. The results show that all tumors exhibit a different signature despite the same diagnosis. Above all, a high inter-tumor heterogeneity emerges. The evolutionary dynamics of all identified mutations within each region underline the questionable value of a single biopsy and thus the therapeutic approach for the patient. Multiregional collection and subsequent sequencing are essential to try to address the clinical challenge of precision medicine. Especially in glioblastoma, this approach could provide powerful support to pathologists and oncologists in evaluating the diagnosis and defining the best treatment option.
Identifiants
pubmed: 33922652
pii: cancers13092044
doi: 10.3390/cancers13092044
pmc: PMC8122908
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Sci Rep. 2016 Oct 04;6:34556
pubmed: 27698411
Cancers (Basel). 2020 Oct 21;12(10):
pubmed: 33096700
Front Mol Biosci. 2020 Sep 08;7:562798
pubmed: 33102518
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cells. 2021 Jan 18;10(1):
pubmed: 33477668
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Genome Biol. 2014 Dec 03;15(12):530
pubmed: 25608559
Sci Rep. 2016 Mar 04;6:22477
pubmed: 26940435
FASEB J. 2020 Jan;34(1):1710-1727
pubmed: 31914660
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Genome Res. 2015 Mar;25(3):316-27
pubmed: 25650244
Neuro Oncol. 2018 Mar 27;20(4):472-483
pubmed: 29244145
Cancer Res. 2011 Jun 15;71(12):4055-60
pubmed: 21628493
BMC Cancer. 2020 Nov 10;20(1):1076
pubmed: 33167919
Nat Genet. 2014 May;46(5):444-450
pubmed: 24705251
Oncotarget. 2018 May 8;9(35):24014-24027
pubmed: 29844869
Tumour Biol. 2016 Oct 7;:
pubmed: 27718125
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Sci Rep. 2020 Jul 15;10(1):11622
pubmed: 32669604
Acta Neuropathol Commun. 2015 Jun 20;3:34
pubmed: 26091668
Elife. 2020 Jan 15;9:
pubmed: 31939734
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Genes Dev. 2013 Jul 1;27(13):1462-72
pubmed: 23796897
Cancers (Basel). 2019 Mar 01;11(3):
pubmed: 30832246
PLoS Comput Biol. 2020 Feb 26;16(2):e1007672
pubmed: 32101537
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
Trends Cancer. 2015 Dec;1(4):252-265
pubmed: 27088132
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Ann Oncol. 2019 Mar 1;30(3):456-463
pubmed: 30452544
Curr Top Microbiol Immunol. 2010;347:279-96
pubmed: 20535652
Arch Pathol Lab Med. 2017 Dec;141(12):1633-1645
pubmed: 29189064
Cell. 2020 Jan 9;180(1):188-204.e22
pubmed: 31883794
Nat Genet. 2013 Mar;45(3):253-61
pubmed: 23354438
J Exp Clin Cancer Res. 2019 Jun 20;38(1):270
pubmed: 31221203
Immunity. 2019 Sep 17;51(3):535-547.e9
pubmed: 31519498
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Clin Cancer Res. 2019 Jun 1;25(11):3259-3265
pubmed: 30796037
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Asian Pac J Cancer Prev. ;18(1):3-9
pubmed: 28239999
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Cancer Med. 2019 Jun;8(6):2705-2716
pubmed: 30950204
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Mol Oncol. 2020 Nov;14(11):2727-2743
pubmed: 32885540
J Clin Oncol. 2016 Nov 1;34(31):3803-3815
pubmed: 27621407
Acta Neuropathol Commun. 2019 Jun 10;7(1):92
pubmed: 31177992
Front Genet. 2020 Feb 07;10:1371
pubmed: 32117420
Mod Pathol. 2020 Feb;33(2):179-187
pubmed: 31028364
F1000Res. 2018 Aug 24;7:1338
pubmed: 30254741
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020420
Neuro Oncol. 2013 Feb;15(2):198-207
pubmed: 23262510
Front Oncol. 2019 Jun 07;9:482
pubmed: 31231613
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
Genes Dev. 2008 Mar 1;22(5):559-74
pubmed: 18316475
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
World Neurosurg. 2019 Nov;131:252-263.e2
pubmed: 31376551
Oncogene. 2013 Aug 15;32(33):3798-808
pubmed: 22986533
Acta Neuropathol Commun. 2020 Jun 3;8(1):80
pubmed: 32493417
Oncotarget. 2016 May 31;7(22):33440-50
pubmed: 26967052
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
NPJ Precis Oncol. 2017 Sep 18;1(1):33
pubmed: 29872714